Comparing two weight-loss surgeries for type 2 diabetes in adults
Compares sleeve gastrectomy with bypass against sleeve gastrectomy alone in adults with type 2 diabetes.
Key facts
- Who runs it
- Seoul National University Bundang Hospital
- Where
- Seongnam-si, South KoreaSee the site
- Trial code
- Registry title
- Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 130 people, planned
- Started
- 3 Jan 2022
- Expected to end
- 3 Jan 2036
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Duodenojejunal bypass
- Sleeve gastrectomy
- Record updated
- 27 January 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes and a high body weight whose blood sugar is still poorly controlled. It compares two weight-loss operations.
- Age
- Over 18 years
- Sex
- All sexes can join
- Disease stage
- Type 2 diabetes for 10 years or less, with poor blood sugar control despite treatment. Must use insulin, or have HbA1c 7.0% (53 mmol/mol) or higher while taking diabetes medicine. C-peptide level must be higher than 1.0 ng/mL.
- Earlier treatment
- No earlier metabolic surgery for type 2 diabetes. No earlier stomach or gut surgery that could affect the result.
- Biomarker or test result
- BMI 27.5 kg/m2 or higher. C-peptide higher than 1.0 ng/mL. HbA1c 7.0% (53 mmol/mol) or higher if not using insulin.
Main reasons for not taking part
- Severe acid reflux that is not controlled (LA classification C or more)
- Earlier metabolic surgery for type 2 diabetes
- Earlier stomach or gut surgery that may affect the result
- More than 3 psychiatric drugs because of poorly controlled psychiatric illness
- Suicide attempt or treatment for alcohol or drug abuse in the last 12 months
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age over 18 years
- BMI equal to or greater than 27.5 kg/m2
- T2DM duration ≤ 10 years
- Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication
- C-peptide level higher than 1.0 ng/mL
- Presence of type 2 diabetes fulfilling the following criteria
- Consent to not become pregnant for at least 1 year after surgery
- Willingness to provide voluntary informed consent
Who cannot take part
- History of previous metabolic surgery for T2DM
- Treatment for alcohol and drug abuse within the last 12 months
- History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery
- Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders
- Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)
- Suicidal attempts within the last 12 months
- Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation)
- Unsuitability as per the discretion of the researcher
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Young Suk ParkTaking people
About the trial
What the trial wants to find out
In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).
Read full original descriptionShow less
This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.
The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group
The 2 groups in the trial
- SG groupExisting treatment, for comparison
Patients undergoing sleeve gastrectomy
Treatment: Sleeve gastrectomy
- DJB groupTreatment being tested
Patients undergoing duodenojejunal bypass with sleeve gastrectomy
Treatment: Duodenojejunal bypass
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
- Plain-language title
- Comparing two weight-loss surgeries for type 2 diabetes in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 January 2022